PRKAA1 and metabolic dysfunction-associated steatotic liver disease: Finally, the absence of validation using human clinical samples—such as liver tissue or serum from NAFLD patients—prevents confirmation of whether rhein modulates AMPK signaling and its downstream targets in a clinically relevant context.